Compass Pathways may be the first to benefit from an accelerated approval process.

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Towards that end in 2018, it received FDA's Breakthrough Therapy designation for COMP360 in the treatment of TRD. In 11/2021 it announced positive results from its phase 2b trial which was written up in an 11/2022 article in NEJM. In 2025, it commenced a pivotal trial program for COMP360. It consisted of:

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the company received breakthrough therapy designation from ...

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Earlier this month, COMPASS Pathways welcomed a White House Executive Order aimed at accelerating treatments for serious mental illness, as it reported two positive phase 3 trials of its COMP360 synthetic psilocybin in treatment-resistant depression and advanced a rolling FDA submission.